Ghent University Academic Bibliography

Advanced

Aberrant methylation of candidate tumor suppressor genes in neuroblastoma

Jasmien Hoebeeck UGent, Evi Michels UGent, Filip Pattyn, Valerie Combaret, Joelle Vermeulen, Nurten Yigit UGent, Claire Hoyoux, Genevieve Laureys UGent, Anne De Paepe UGent, Franki Speleman UGent, et al. (2009) CANCER LETTERS. 273(2). p.336-346
abstract
CpG island hypermethylation has been recognized as an alternative mechanism for tumor suppressor gene inactivation. In this study, we performed methylation-specific PCR (MSP) to investigate the methylation status of 10 selected tumor suppressor genes in neuroblastoma. Seven of the investigated genes (CD44, RASSF1A, CASP8, PTEN, ZMYND10, CDH1, PRDM2) showed high frequencies (>= 30%) of methylation in 33 neuroblastoma cell lines. In 42 primary neuroblastoma tumors, the frequencies of methylation were 69%, CD44; 71%, RASSF1A; 56%, CASP8; 25%, PTEN; 15%, ZMYND10; 8%, CDH1; and 0%, PRDM2. Furthermore, CASP8 and CDH1 hypermethylation was significantly associated with poor event-free survival. Meta-analysis of 115 neuroblastoma tumors demonstrated a significant correlation between CASP8 methylation and MYCN amplification. In addition, there was a correlation between ZMYND10 methylation and MYCN amplification. The MSP data, together with optimized mRNA re-expression experiments (in terms of concentration and time of treatment and use of proper reference genes) further strengthen the notion that epigenetic alterations could play a significant role in NB oncogenesis. This study thus warrants the need for a global profiling of gene promoter hypermethylation to identify genome-wide aberrantly methylated genes in order to further understand neuroblastoma pathogenesis and to identify prognostic methylation markers.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
journal title
CANCER LETTERS
Cancer Lett.
volume
273
issue
2
pages
336 - 346
Web of Science type
Article
Web of Science id
000262582100021
JCR category
ONCOLOGY
JCR impact factor
3.741 (2009)
JCR rank
52/163 (2009)
JCR quartile
2 (2009)
ISSN
0304-3835
DOI
10.1016/j.canlet.2008.08.019
language
English
UGent publication?
yes
classification
A1
id
516097
handle
http://hdl.handle.net/1854/LU-516097
date created
2009-03-09 16:14:59
date last changed
2016-12-19 15:40:30
@article{516097,
  abstract     = {CpG island hypermethylation has been recognized as an alternative mechanism for tumor suppressor gene inactivation. In this study, we performed methylation-specific PCR (MSP) to investigate the methylation status of 10 selected tumor suppressor genes in neuroblastoma. Seven of the investigated genes (CD44, RASSF1A, CASP8, PTEN, ZMYND10, CDH1, PRDM2) showed high frequencies ({\textrangle}= 30\%) of methylation in 33 neuroblastoma cell lines. In 42 primary neuroblastoma tumors, the frequencies of methylation were 69\%, CD44; 71\%, RASSF1A; 56\%, CASP8; 25\%, PTEN; 15\%, ZMYND10; 8\%, CDH1; and 0\%, PRDM2. Furthermore, CASP8 and CDH1 hypermethylation was significantly associated with poor event-free survival. Meta-analysis of 115 neuroblastoma tumors demonstrated a significant correlation between CASP8 methylation and MYCN amplification. In addition, there was a correlation between ZMYND10 methylation and MYCN amplification. The MSP data, together with optimized mRNA re-expression experiments (in terms of concentration and time of treatment and use of proper reference genes) further strengthen the notion that epigenetic alterations could play a significant role in NB oncogenesis. This study thus warrants the need for a global profiling of gene promoter hypermethylation to identify genome-wide aberrantly methylated genes in order to further understand neuroblastoma pathogenesis and to identify prognostic methylation markers.},
  author       = {Hoebeeck, Jasmien and Michels, Evi and Pattyn, Filip and Combaret, Valerie and Vermeulen, Joelle and Yigit, Nurten and Hoyoux, Claire and Laureys, Genevieve and De Paepe, Anne and Speleman, Franki and Vandesompele, Jo},
  issn         = {0304-3835},
  journal      = {CANCER LETTERS},
  language     = {eng},
  number       = {2},
  pages        = {336--346},
  title        = {Aberrant methylation of candidate tumor suppressor genes in neuroblastoma},
  url          = {http://dx.doi.org/10.1016/j.canlet.2008.08.019},
  volume       = {273},
  year         = {2009},
}

Chicago
Hoebeeck, Jasmien, Evi Michels, Filip Pattyn, Valerie Combaret, Joelle Vermeulen, Nurten Yigit, Claire Hoyoux, et al. 2009. “Aberrant Methylation of Candidate Tumor Suppressor Genes in Neuroblastoma.” Cancer Letters 273 (2): 336–346.
APA
Hoebeeck, J., Michels, E., Pattyn, F., Combaret, V., Vermeulen, J., Yigit, N., Hoyoux, C., et al. (2009). Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. CANCER LETTERS, 273(2), 336–346.
Vancouver
1.
Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. CANCER LETTERS. 2009;273(2):336–46.
MLA
Hoebeeck, Jasmien, Evi Michels, Filip Pattyn, et al. “Aberrant Methylation of Candidate Tumor Suppressor Genes in Neuroblastoma.” CANCER LETTERS 273.2 (2009): 336–346. Print.